Fibrogen Announces Receipt of Patent On Induction of Tissue, Bone and Cartilage Formation Using CTGF.SAN FRANCISCO--(BW HealthWire)--Dec. 8, 1998--FibroGen, Inc. today announced receipt of U.S. Patent No. 05837258, issued on November 17, 1998, for the use of connective tissue growth factor (CTGF CTGF connective tissue growth factor CTGF Cytokine-Transforming Growth Factor CTGF Clean Tanks, Gas Free ) to induce the repair of connective tissue, including bone, cartilage and skin. The inventor on this patent, Dr. Gary Grotendorst, is a FibroGen collaborator and a professor at the department of cell biology and anatomy at the University of Miami This article is about the university in Coral Gables, Florida. For the university in Oxford, Ohio, see Miami University. The University of Miami (also known as Miami of Florida,[2] UM,[3] or just The U . In the United States, doctors perform more than 4 million procedures annually to repair damage to cartilage, bone and skin which result from traumatic injuries and complications from other chronic medical conditions, such as arthritis and diabetic ulcers. "There is a tremendous interest in therapeutics which can improve these medical outcomes, and we are excited about the potential to utilize our proprietary technology on CTGF to develop therapeutic agents for wound repair and tissue engineering," said Thomas B. Neff, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and President of FibroGen. This most recently issued patent builds on existing proprietary technology, including U.S. Patent No. 05770209, issued on June 23, 1998, for the use of CTGF to accelerate wound healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by alone or in combination with transforming growth factor beta transforming growth factor beta (TGF-β), n a substance that is produced by bone cells and platelets to promote bone regeneration and wound healing. (TGF-Beta). FibroGen holds the exclusive worldwide license to intellectual property related to CTGF and its use as an inductive agent. FibroGen's extensive proprietary position on CTGF includes composition and methods patents, related antibodies, and the nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. sequence encoding CTGF. CTGF is produced by connective tissue cells after activation by TGF-Beta and certain bone morphogenic proteins, which are important mediators of repair. CTGF works by sending signals that trigger biological responses critical to tissue development, repair and regeneration. FibroGen also has a program utilizing CTGF as a target for the development of anti-fibrotic therapeutics since it is overexpressed in these conditions. FibroGen, a privately held biotechnology company, uses its expertise in extracellular matrix extracellular matrix (eksˈ·tr  ·selˑ·y biology to discover and develop innovative treatments for fibroproliferative disorders, such as deep organ fibrosis and complications arising from surgical scarring, as well as therapeutics related to tissue repair and regeneration. FibroGen is also a leader in the development and production of recombinant human collagen for use in the medical device and tissue sealant markets as well as recombinant gelatin gelatin or animal jelly, foodstuff obtained from connective tissue (found in hoofs, bones, tendons, ligaments, and cartilage) of vertebrate animals by the action of boiling water or dilute acid. for capsules, vaccine stabilizers and other pharmaceutical applications. More information on FibroGen and copies of previous press releases are available at www.businesswire.com/cnn/fibro.htm.
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion